Trophogen, Inc.
From Wikipedia, the free encyclopedia
| Trophogen, Inc. | |
 |
|
| Type | Private |
|---|---|
| Founded | 2001 |
| Headquarters | Rockville, Maryland, 39 05' 48 N and 77 07'47 W |
| Key people | Bruce Weintraub, COO & CSO and Mariusz Szkudlinski, Vice President for Research and Development |
| Industry | Biotechnology |
| Employees | 7 (2006) |
| Website | http://www.trophogen.com/ |
Trophogen, Inc. is a biotechnology company based in Rockville, Maryland.
Trophogen was formed by two molecular endocrinologists who spent numerous years as academians at NIH and the University of Maryland, Baltimore before striking out on their own to launch their first entrepreneurial endeavor. Operating with staff of five scientists, their research is focused on the development of high affinity glycoprotein hormone and related growth factor analogs (FSH, LH and TSH) for targeted therapy and imaging of ovarian, breast, prostate, testicular and thyroid cancers as well as for human and animal infertility.
Lead Product Candidates
1.- LH- and FSH superagonist- radionuclide or –toxin for the targeted therapy of ovarian cancer
2.- LH superagonist- radionuclide or –toxin for the targeted therapy of breast and prostate cancer
3.- TSH superagonist- radionuclide or –toxin for the targeted therapy of thyroid cancer
4.- TSH superagonist for enhancing 131I diagnostic scanning and treatment of thyroid cancer
3.- Labeled TSH superagonist imaging agent for thyroid cancer
6.- FSH and LH superagonist for the treatment of human and animal infertility
7.- VEGF superagonist for therapeutic targeting of tumor vasculature, vascular imaging and as a media supplement for endothelial and stem cell proliferation/differentiation
